|
Dr. Pykett was appointed President of BLSI in February 2005. He joined the company as Executive Vice President and Chief Operating Officer in November 2004. Prior to joining the Company, Dr. Pykett was President of CyGenics, Ltd., a fully integrated global cell therapy biotechnology company, where he was responsible for global technology and clinical development, business development, licensing, and partnerships. Prior to CyGenics, Dr. Pykett was Co-Founder, President, Chief Executive Officer, and a member of the Board of Directors of Cytomatrix, LLC, and President of Cordlife, Pte Ltd., which acquired Cytomatrix in 2003. Dr. Pykett graduated Phi Beta Kappa, Summa Cum Laude from Amherst College, holds a veterinary degree, Phi Zeta, Summa Cum Laude, and doctorate in molecular biology from the University of Pennsylvania, and received an M.B.A. degree Beta Gamma Sigma from Northeastern University. He completed post-doctoral fellowships at the University of Pennsylvania and Harvard University. In his scientific research, Dr. Pykett focused on understanding the molecular basis of cancer. Dr. Pykett held an adjunct faculty position at the Harvard School of Public Health from 1997 to 2002, and currently serves on the Advisory Board of the Center for Enterprise Growth at Northeastern University. Additionally, he serves as a Director of CyGenics, Ltd., ADVENTRX Pharmaceuticals, Inc., and of Oramax, LLC. | 